Prostate Cancer Test Not Worth Risk, Advisory Panel Says

Law360, New York (May 22, 2012, 3:44 PM EDT) -- A government-backed panel of independent medical experts on Monday recommended against use of a controversial test for prostate cancer, drawing scorn from industry organizations and potentially rekindling a smoldering debate over the risks of overtreatment.

The U.S. Preventive Services Task Force, which consists largely of primary care physicians and specialists, gave the prostate-specific antigen test its lowest grade of D, which applies when the group has "moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits."

"There is...
To view the full article, register now.